Your session is about to expire
← Back to Search
Duvelisib + Romidepsin/Bortezomib for T-Cell Lymphoma
Study Summary
This trial is testing if duvelisib is safe for humans.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am receiving or have received therapy to prevent cancer recurrence, not for T-cell lymphoma.I stopped taking romidepsin before because of its side effects.I stopped taking duvelisib because it was causing harmful side effects.I stopped a proteasome inhibitor treatment because of side effects.I do not have an active CMV infection requiring treatment.I am currently fighting an infection that needs strong medication.I have a history of liver disease or I currently abuse alcohol.I have Hepatitis B but meet the criteria for treatment in this study.I have an active Epstein-Barr virus infection not related to my lymphoma.I am currently receiving treatment for another cancer besides T-cell lymphoma.My cancer has spread to my brain or its coverings.I have moderate to severe nerve damage not related to the spine.I have had surgery or have a condition that could affect how drugs are absorbed in my body.I have HIV, HBV, or HCV and need antiviral treatment.My T-cell lymphoma has worsened after at least one treatment.I stopped my cancer treatment at least 3 weeks ago.I can take care of myself and perform daily activities.My cancer can be measured by tests.I don't have serious heart conditions or uncontrolled high blood pressure.I am 18 years old or older.I finished any cancer surgery or radiation at least 2 weeks ago and any side effects have mostly gone away.I stopped short-term steroids 6 days ago or have been on stable steroids for 30 days.I can use topical steroids for my skin cancer without restrictions.I am a woman capable of becoming pregnant.I have not received a live vaccine in the last 6 weeks.
- Group 1: Romidepsin + duvelisib
- Group 2: Bortezomib + duvelisib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are any fresh participants being sought for this trial?
"This clinical trial has concluded its recruitment. Initially posted on May 1st 2016, the study was last updated on September 20th 2022. For those seeking alternative trials, 1733 studies for lymphoma and 174 ones concerning duvelisib are currently enrolling patients."
How many individuals are being administered care in this trial?
"Unfortunately, this clinical trial is not currently accepting candidates. Initially posted on May 1st 2016 and last updated on September 20th 2022, it has been placed in stasis for the time being. That said, there are 1733 medical studies searching for participants with lymphoma and 174 trials exploring duvelisib that may be open to applicants."
In what maladies is duvelisib typically prescribed?
"Duvelisib is a viable therapy for refractory anemias, mantle cell lymphoma (mcl), and follicular lymphoma."
Are there any American research centers participating in this endeavor?
"The trial encompasses 7 different medical sites, with Memorial Sloan Kettering Cancer Center in New york at the forefront. Additionally, Memoral Sloan Kettering Westchester (Limited protocol activities) can be found in Harrison and Memorial Sloan Kettering Nassau (Limited protocol activities) is located in Uniondale. The other 4 locations are also participating."
Are there any other studies that have evaluated the efficacy of duvelisib?
"First tested by the National Institutes of Health Clinical Center in 2004, duvelisib has since been subject to 438 completed clinical trials. Currently, 174 studies are actively recruiting participants across New york and New jersey."
Are there any observed safety concerns with duvelisib treatments?
"There is little information to support the safety of duvelisib, so it has been given a score of 1 on our scale."
Share this study with friends
Copy Link
Messenger